Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
LEIDEN, the Netherlands, April 10, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 10, 2017 at 15:00 CET, at the offices of Allen & Overy at Apollolaan 15, 1077 AB Amsterdam, the Netherlands.
All relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Financial Information’. The documents will also be made available on the SEC's website at www.sec.gov.
A live webcast of the event will be accessible in the ‘Investor Relations’ section of ProQR’s website under ‘Events and Presentations’.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Contact:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
[email protected]
